BioRestorative Therapies, Inc. (NASDAQ:BRTX) Sees Significant Decline in Short Interest

BioRestorative Therapies, Inc. (NASDAQ:BRTX) saw a large decrease in short interest in the month of June. As of June 30th, there was short interest totalling 268,800 shares, a decrease of 85.6% from the June 15th total of 1,870,000 shares. Based on an average daily trading volume, of 2,120,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 4.9% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, Roth Mkm reiterated a “buy” rating and issued a $15.00 price target on shares of BioRestorative Therapies in a report on Wednesday, June 12th.

BioRestorative Therapies Price Performance

Shares of NASDAQ:BRTX opened at $1.82 on Friday. BioRestorative Therapies has a 1 year low of $1.03 and a 1 year high of $3.67. The firm has a market capitalization of $12.32 million, a price-to-earnings ratio of -0.79 and a beta of 63.43. The business’s 50 day moving average price is $1.58 and its 200-day moving average price is $1.53.

BioRestorative Therapies (NASDAQ:BRTX) last announced its earnings results on Tuesday, June 11th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.03 million. BioRestorative Therapies had a negative net margin of 7,303.33% and a negative return on equity of 96.09%. On average, sell-side analysts expect that BioRestorative Therapies will post -2.36 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BioRestorative Therapies stock. StoneX Group Inc. purchased a new position in shares of BioRestorative Therapies, Inc. (NASDAQ:BRTX) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 34,850 shares of the company’s stock, valued at approximately $48,000. StoneX Group Inc. owned 0.51% of BioRestorative Therapies as of its most recent SEC filing. Institutional investors and hedge funds own 69.38% of the company’s stock.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.